Browsing Tag

COMPASS Pathways

First clinical study results of psilocybin treatment in anorexia nervosa published in Nature…

Jason Junior Jul 25, 2023

LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of…

Health

COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2…

Jason Junior Jul 17, 2023

Results of COMPASS Pathways’ open-label study of COMP360 psilocybin treatment, alongside SSRI antidepressants, suggest that SSRIs do not interfere with the potential therapeutic effect of COMP360 LONDON, July 17, 2023 (GLOBE NEWSWIRE)…

Health

Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin

Jason Junior Jul 13, 2023

Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment.Authors highlight the need for clarity in terminology…

Health

COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented…

Jason Junior Dec 8, 2022

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II bipolar disorder New data from…